Evoke Pharma, Inc. (EVOK)
NASDAQ: EVOK · IEX Real-Time Price · USD
1.66
-0.09 (-5.14%)
At close:
May 31, 2023, 2:24 PM
1.67
+0.01 (0.60%)
After-hours:
May 31, 2023, 4:45 PM EDT
Company Description
Evoke Pharma, Inc., a specialty pharmaceutical company, primarily focuses on the development and commercialization of drugs for the treatment of gastroenterological disorders and diseases.
It is developing Gimoti, a metoclopramide nasal spray that has completed Phase 3 clinical trials to treat symptoms associated with acute and recurrent diabetic gastroparesis in females.
The company markets its products to gastroenterologists, internal medicine specialists, primary care physicians, and select health care providers.
Evoke Pharma, Inc. was incorporated in 2007 and is headquartered in Solana Beach, California.
Evoke Pharma, Inc.
| Country | United States |
| Founded | 2007 |
| IPO Date | Sep 25, 2013 |
| Industry | Drug Manufacturers - Specialty & Generic |
| Sector | Healthcare |
| Employees | 4 |
| CEO | David A. Gonyer R.Ph. |
Contact Details
Address:
420 Stevens Avenue, Suite 370 Solana Beach, California 92075 United States | |
| Phone | 858-345-1494 |
| Website | evokepharma.com |
Stock Details
| Ticker Symbol | EVOK |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001403708 |
| CUSIP Number | 30049G104 |
| ISIN Number | US30049G1040 |
| Employer ID | 20-8447886 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| David A. Gonyer | Co-Founder, Chief Executive Officer, President and Director |
| Matthew J. D'Onofrio | Co-Founder, Chief Business Officer, Executive Vice President, Treasurer and Secretary |
| Dr. Marilyn R. Carlson | Chief Medical Officer |
| Christopher Quesenberry | Chief Commercial Officer - Gimoti (TM) |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| May 26, 2023 | 8-K | Current Report |
| May 18, 2023 | CT ORDER | Filing |
| May 15, 2023 | 8-K | Current Report |
| May 15, 2023 | 10-Q | Quarterly Report |
| May 11, 2023 | 8-K | Current Report |
| May 9, 2023 | 8-K | Current Report |
| May 1, 2023 | 8-K | Current Report |
| Apr 20, 2023 | 8-K | Current Report |
| Apr 6, 2023 | 8-K | Current Report |
| Mar 29, 2023 | DEF 14A | Other definitive proxy statements |